1. Signaling Pathways
  2. Antibody-drug Conjugate/ADC Related
  3. ADC Payload

ADC Cytotoxin

ADC payloads are cytotoxic agents that induce target cell death in Antibody Drug Conjugates (ADCs). An ADC is a targeted agent composed with a monoclonal antibody, a linker and a payload. The payload is the most important component as it determines the potency to kill cancer cells of an ADC.

There are many payloads which are currently being used such as Calicheamicins, Duocarmycins, Pyrrolobenzodiazepines (PBDs), Camptothecins, Daunorubicins/Doxorubicins, Auristatins and Maytansinoids. They can be divided in two classes based on their mechanism of action, DNA damaging agents and tubulin inhibitors. Among them Calicheamicins, Duocarmycins and PBDs are DNA minor grove binders, Camptothecins and Daunorubicins/Doxorubicins are topoisomerase inhibitors, which are DNA damaging agents. Auristatins and Maytansinoids are tubulin inhibitors.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-148435
    Glucocorticoid receptor agonist-2
    99.65%
    Glucocorticoid receptor agonist-2 (compound 21) is an glucocorticoid receptor agonist with an IC50 value of 6.6 nM. Glucocorticoid receptor agonist-2 can be used to synthesize anti-inflammatory ADC molecules. Glucocorticoid receptor agonist-2 is an active reference of ABBV-3373.
    Glucocorticoid receptor agonist-2
  • HY-43564
    Exatecan Intermediate 5
    99.98%
    Exatecan Intermediate 5 is the intermediate of Exatecan (HY-13631) And Exatecan (DX-8951) is a DNA topoisomerase I inhibitor with an IC50 value of 2.2 μM (0.975 μg/mL) that can be used in cancer research. Exatecan Intermediate 5 can be used to synthesize Antibody-Drug Conjugates (ADCs).
    Exatecan Intermediate 5
  • HY-130082
    DM4-SMe
    99.99%
    DM4-SMe is a metabolite of antibody-maytansin conjugates (AMCs) and a tubulin inhibitor, and also a cytotoxic moiety of antibody-drug conjugates (ADCs), which can be linked to antibody through disulfide bond or stable thioether bond. DM4-SMe inhibits KB cells with an IC50 of 0.026 nM.
    DM4-SMe
  • HY-128914
    Tubulysin
    99.53%
    The Tubulysin family of secondary metabolites was originally isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. These compounds are potent microtubule destabilizers and anti-microtubule toxins (anti-microtubule toxins), with effective IC50 concentrations against multidrug-resistant cancer cell lines. In the picomole range. Tubulysins are ideal candidates for incorporation into small active molecule conjugate (SMDC) delivery systems and are commonly used in ADC synthesis as ADC cytotoxins (ADC Cytotoxin).
    Tubulysin
  • HY-145149
    Duostatin 5
    99.76%
    Duostatin 5 is a ADC Cytotoxin designed based on MMAF (HY-15579) and can be used to synthesize ADCs. The preparation of Duostatin 5 has the advantages of fewer synthetic steps, simple operation, less difficulty in quality control, and more stable chemical synthesis process. Duostatin 5 can be linked to the antibody targeting 5T4 (ZV05) by cross-linking with interchain cysteines through a disubstituted C-Lock linker. Duostatin 5 is a click chemistry reagent. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-driven alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups[1][2].
    Duostatin 5
  • HY-156174
    E104
    98.02%
    E104 (compound 1) is a potent and selective TLR7 agonist. E104 can be delivered by antibody-drug conjugate (ADC) technology to elicit potent anticancer activity. E104 induces the activation of mouse macrophages and hPBMCs.
    E104
  • HY-163295
    BTK degrader-1
    99.40%
    BTK degrader-1 (compound 1) is a Bruton’s tyrosine kinase (BTK) bifunctional degrader that can be conjugated with CD79b. BTK degrader-1 (compound 1) has anti-tumor effect.
    BTK degrader-1
  • HY-13631M
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan is an ADC cytotoxin.
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan
  • HY-132160A
    7-Aminomethyl-10-methyl-11-fluoro camptothecin TFA
    7-Aminomethyl-10-methyl-11-fluoro camptothecin TFA is a cytotoxin of MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin (HY-132158). 7-Aminomethyl-10-methyl-11-fluoro camptothecin TFA can be used for the synthesis of camptothecin antibody-drug conjugate (ADC).
    7-Aminomethyl-10-methyl-11-fluoro camptothecin TFA
  • HY-13704R
    SN-38 (Standard)
    SN-38 (Standard) is the analytical standard of SN-38. This product is intended for research and analytical applications. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254).
    SN-38 (Standard)
  • HY-14648G
    Dexamethasone (GMP)
    Dexamethasone (Hexadecadrol) (GMP) is Dexamethasone (HY-14648) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Dexamethasone is an agonist of glucocorticoid receptor.
    Dexamethasone (GMP)
  • HY-128873
    Duocarmycin GA
    99.00%
    Duocarmycin GA is an antibody agent conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin GA can be used against multi-agent resistant cell lines.
    Duocarmycin GA
  • HY-102001
    Tomaymycin DM
    98.01%
    Tomaymycin DM is a tomaymycin derivative, PBD monomer, and DNA alkylating agent. Tomaymycin DM can serve as a payload in tumor-targeting antibody-conjugated active molecules (ADCs).
    Tomaymycin DM
  • HY-153797
    Dox-btn2
    Dox-btn2 is a biotin labeled Doxorubicin (HY-15142A), with a biotin label at the point of conjugation to doxorubicin at 3'-NH2. Dox-btn2 can be used for cell imaging. While Doxorubicin is mainly accumulated in the nucleus, while Dox-btn2 is mainly located in the cytoplasm.
    Dox-btn2
  • HY-15579AS
    MMAF-d8 hydrochloride
    99.70%
    MMAF-d8 (hydrochloride)e is a deuterated form of MMAF hydrochloride, which is a microtubule disrupting agent.
    MMAF-d<sub>8</sub> hydrochloride
  • HY-129379
    DC0-NH2
    DC0-NH2 is an effector moiety for ADC and a simplified analog of DC1 with better stability. DC0-NH2 is about 1000-fold more cytotoxic than commonly used anticancer agents (ex. Doxorubicin). DC0-NH2 can bind to the minor groove of DNA, followed by alkylation of adenine residues by its propabenzindole (CBI) component.
    DC0-NH2
  • HY-125331
    DRF-1042
    98.06%
    DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-agent resistance (MDR) phenotype.
    DRF-1042
  • HY-164860
    Glucocorticoid receptor agonist-5
    99.95%
    Glucocorticoid receptor agonist-5 (compound 4), a glucocorticoid molecule, is a potent glucocorticoid receptor agonist. Glucocorticoid receptor agonist-5 shows anti-inflammatory and immunosuppressive activity. Glucocorticoid receptor agonist-5 is used as an ADC Cytotoxin for antibody-drug conjugate.
    Glucocorticoid receptor agonist-5
  • HY-41055
    Taltobulin intermediate-4
    99.57%
    Taltobulin intermediate-4 is an intermediate in the synthesis of Taltobulin (HY-15584). Taltobulin is a common toxin component in ADC preparation (ADC Cytotoxin), and it is also a powerful tubulin (Microtubule/Tubulin) inhibitor. Taltobulin disrupts tubulin polymerization, induces mitotic arrest, and induces apoptosis.
    Taltobulin intermediate-4
  • HY-20584
    10-Deacetyl-7-xylosyl paclitaxel
    99.65%
    10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel (a microtubule stabilizing agent; enhances tubulin polymerization) derivative with improved pharmacological features.
    10-Deacetyl-7-xylosyl paclitaxel
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.